Send to

Choose Destination
PLoS One. 2013;8(3):e59288. doi: 10.1371/journal.pone.0059288. Epub 2013 Mar 26.

A systematic in silico search for target similarity identifies several approved drugs with potential activity against the Plasmodium falciparum apicoplast.

Author information

Instituto de Patologia Tropical e Saúde Pública/Universidade Federal de Goiás/Goiânia, Brazil.

Erratum in

  • PLoS One. 2013;8(6). doi:10.1371/annotation/0bbd3579-5212-4dcf-a5ef-dd3d8e26f287.


Most of the drugs in use against Plasmodium falciparum share similar modes of action and, consequently, there is a need to identify alternative potential drug targets. Here, we focus on the apicoplast, a malarial plastid-like organelle of algal source which evolved through secondary endosymbiosis. We undertake a systematic in silico target-based identification approach for detecting drugs already approved for clinical use in humans that may be able to interfere with the P. falciparum apicoplast. The P. falciparum genome database GeneDB was used to compile a list of ≈600 proteins containing apicoplast signal peptides. Each of these proteins was treated as a potential drug target and its predicted sequence was used to interrogate three different freely available databases (Therapeutic Target Database, DrugBank and STITCH3.1) that provide synoptic data on drugs and their primary or putative drug targets. We were able to identify several drugs that are expected to interact with forty-seven (47) peptides predicted to be involved in the biology of the P. falciparum apicoplast. Fifteen (15) of these putative targets are predicted to have affinity to drugs that are already approved for clinical use but have never been evaluated against malaria parasites. We suggest that some of these drugs should be experimentally tested and/or serve as leads for engineering new antimalarials.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center